News

Germany-based, Merck KgaA is going to launch Parteck ODT, a directly compressible excipient developed for fast-acting orally disintegrating tablets, at the CPhI Worldwide in Madrid. According to the

Santarus and Norgine have entered into a licensing agreement granting exclusive rights to Norgine to develop, manufacture and commercialise prescription immediate-release Zegerid products. It incorporates the proton pump

Onyx Pharmaceuticals (Onyx) has signed an agreement to acquire Proteolix, a biopharmaceutical company focused on novel therapies that target the proteasome for the treatment of hematological malignancies and

BioAlliance Pharma (BioAlliance) has got the approval from the French Drug Agency (AFSSaPS) to enter first phase I clinical trial for Fentanyl Lauriad. Reportedly, the clinical trial will

DARA BioSciences (DARA) has entered into an Addendum and First Amendment to Material Transfer Agreement with America Stem Cell (ASC), pursuant to which the Material Transfer Agreement between

Sequella has received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID). The

Depomed has reported top-line results from the BREEZE 1 and 2 phase 3 clinical trials evaluating the safety and efficacy of Serada. Its an investigational non-hormonal extended release

Phyton Biotech (PB), an affiliate of Phyton, has purchased the assets of Natural Pharmaceuticals (NPI). Under the terms of the agreement, PB will acquire assets of NPI, which

Celator Pharmaceuticals has completed enrollment in its phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, versus conventional cytarabine and daunorubicin therapy. It was conducted